Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
01-02 April, 2026
Not Confirmed
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Not Confirmed
Not Confirmed
07-09 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CGT Asia
Not Confirmed
Contact SupplierCGT Asia
Industry Trade Show
Not Confirmed
01-02 April, 2026
Industry Trade Show
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
07-09 April, 2026
Digital content
NEWS #PharmaBuzz
30 Apr 2025
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bdr-pharmaceuticals-plans-100-mn-expansion-in-the-us-with-manufacturing-buyouts/articleshow/120764842.cms
02 Jan 2024
// ECONOMIC TIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bdr-pharmaceuticals-introduces-prostate-cancer-treatment-drug-in-oral-solution-form/articleshow/106481524.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
28 Aug 2023
// EXPRESSPHARMA
https://www.expresspharma.in/bdr-pharma-launches-dalbonova-injection-for-acute-bacterial-skin-infections-inject/
03 Jan 2023
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bdr-pharmaceutical-launches-generic-drug-for-treating-prostate-cancer-in-india/articleshow/96708591.cms
31 May 2022
// EXPRESS PHARMA
https://www.expresspharma.in/bdr-pharma-partners-with-varenyam-healthcare-to-launch-sugmadex-in-india/
17 May 2022
// Viswanath Pilla ECONOMIC TIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bdr-pharma-raises-rs-685-crore-from-multiples-other-investors/articleshow/91604230.cms
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
LISTED APIs
About the Company : BDR is a niche player in today's global arena. BDR is specialized in early identification, development and introduction of new fourth generation medicines for life threatening disease.BDR with i...
About the Company : BDR is a niche player in today's global arena. BDR is specialized in early identification, development and introduction of new fourth generation medicines for life threatening disease.BDR with i...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Tuccatinn (tucatinib) is a HER2 inhibitor, approved in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
Lead Product(s): Tucatinib
Therapeutic Area: Oncology Brand Name: Tuccatinn
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2025
Lead Product(s) : Tucatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
India’s CDSCO Clears BDR Pharma To Make & Market Tucatinib Tablets
Details : Tuccatinn (tucatinib) is a HER2 inhibitor, approved in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
Product Name : Tuccatinn
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2025
Details:
Bdenza (enzalutamide) is a small molecule AR inhibitor available in oral solution form, which is approved for the treatment of patients with prostate cancer.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Brand Name: Bdenza
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 02, 2024
Lead Product(s) : Enzalutamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BDR Pharmaceuticals introduces prostate cancer treatment drug in oral solution form
Details : Bdenza (enzalutamide) is a small molecule AR inhibitor available in oral solution form, which is approved for the treatment of patients with prostate cancer.
Product Name : Bdenza
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 02, 2024
Details:
Under the agreement, Procaps will be responsible for registration, branding, marketing and commercialization of 27 oncology molecules for Latin America, including 20 TKIs (Tirosyne Kinase Inhibitors).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Recipient: Procaps Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 07, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Procaps Group
Deal Size : Undisclosed
Deal Type : Agreement
Procaps Group Announces the Expansion of its Oncology Portfolio
Details : Under the agreement, Procaps will be responsible for registration, branding, marketing and commercialization of 27 oncology molecules for Latin America, including 20 TKIs (Tirosyne Kinase Inhibitors).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 07, 2023
Details:
APATIDE (generic version of Apalutamide) is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain and blocks AR nuclear translocation or binding to androgen response elements. Product has been launched in India to treat prostate cancer.
Lead Product(s): Apalutamide
Therapeutic Area: Oncology Brand Name: Apatide
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 03, 2023
Lead Product(s) : Apalutamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BDR Pharmaceutical Launches Generic Drug for Treating Prostate Cancer in India
Details : APATIDE (generic version of Apalutamide) is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain and blocks AR nuclear translocation or binding to androgen response elements. Product has been launched in India to...
Product Name : Apatide
Product Type : HPAPI
Upfront Cash : Inapplicable
January 03, 2023
Details:
BDR Pharma elevates its own standard of the wide range of critical care segment products with launch of biapenem under brand name Biapen to treat intra-abdominal, lower respiratory or complicated urinary tract infections, which will be available in the market shortly.
Lead Product(s): Biapenem
Therapeutic Area: Infections and Infectious Diseases Brand Name: Biapen
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2021
Lead Product(s) : Biapenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BDR Pharma elevates its own standard of the wide range of critical care segment products with launch of biapenem under brand name Biapen to treat intra-abdominal, lower respiratory or complicated urinary tract infections, which will be available in the m...
Product Name : Biapen
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 24, 2021
Details:
Cabozantinib is prescribed for treating patients with progressive, metastatic medullary thyroid cancer (MTC) and as a second-line treatment for renal cell carcinoma apart from treating hepatocellular carcinoma.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 14, 2021
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BDR Pharma Launches Cabozantinib to Treat Metastatic Medullary Thyroid Cancer
Details : Cabozantinib is prescribed for treating patients with progressive, metastatic medullary thyroid cancer (MTC) and as a second-line treatment for renal cell carcinoma apart from treating hepatocellular carcinoma.
Product Name : Cabometyx
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2021
Details:
BDR Pharma has inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.
Lead Product(s): 2-Deoxy-D-Glucose
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Carbohydrate
Recipient: Indian Defence Research And Development Organisation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2021
Lead Product(s) : 2-Deoxy-D-Glucose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Indian Defence Research And Development Organisation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BDR Pharma Inks License Agreement with DRDO to Produce COVID-19 Drug 2-DG
Details : BDR Pharma has inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Undisclosed
July 26, 2021
Details:
Under the partnership, BDR Pharma will be manufacturing & marketing Barikind (baricitinib) which received restricted emergency use approval for use in combination with remdesivir for treating COVID19.
Lead Product(s): Baricitinib,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Barikind
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Mankind Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 24, 2021
Lead Product(s) : Baricitinib,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Mankind Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Mankind Pharma Inks Distribution Pact with BDR Pharmaceuticals for COVID Drug
Details : Under the partnership, BDR Pharma will be manufacturing & marketing Barikind (baricitinib) which received restricted emergency use approval for use in combination with remdesivir for treating COVID19.
Product Name : Barikind
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 24, 2021
Details:
Rucaparib is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2, and 3. BDPARIB is first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the market.
Lead Product(s): Rucaparib Camsylate
Therapeutic Area: Oncology Brand Name: Bdparib
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 27, 2021
Lead Product(s) : Rucaparib Camsylate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rucaparib is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2, and 3. BDPARIB is first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the m...
Product Name : Bdparib
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 27, 2021
Details:
Bdfoie (lenvatinib mesylate), an oral receptor tyrosine kinase inhibitor, launched in India, for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
Lead Product(s): Lenvatinib Mesylate
Therapeutic Area: Oncology Brand Name: Bdfoie
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2020
Lead Product(s) : Lenvatinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BDR Pharma Launches Generic Lenvatinib for Cancer Patients in India
Details : Bdfoie (lenvatinib mesylate), an oral receptor tyrosine kinase inhibitor, launched in India, for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
Product Name : Bdfoie
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
BDR Pharmaceuticals is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find a price of Calcipotriol bulk offered by BDR Pharmaceuticals
Find a price of Omeprazole Sodium bulk offered by BDR Pharmaceuticals
Share 
